Physician profile
James E Alderson
NPI 1609808823
$6,205.62
in general payments reported to CMS, 2019-2025
43 companies · $42.68 in 2025
The $42.68 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,506 · 2020: $1,089 · 2021: $1,557 · 2022: $1,395 · 2023: $579 · 2024: $36.27 · 2025: $42.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $658.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $942.28 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $908.88 | 2019-2023 | |
| Abbvie INC. | $693.82 | 2020-2025 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.90 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $250.59 | 2021-2022 | |
| Eisai INC. | $222.57 | 2020-2022 | |
| Amgen INC. | $218.93 | 2019-2025 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.58 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $177.34 | 2019-2022 | |
| Abbott Laboratories | $168.08 | 2021-2023 | Freestyle Libre 3 |
| Allergan, INC. | $155.35 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $148.91 | 2019-2021 | |
| Lilly USA, LLC | $148.64 | 2019-2021 | |
| Glaxosmithkline, LLC. | $146.00 | 2019-2023 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $140.88 | 2019-2023 | Farxiga |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Alderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.